secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cellectar Biosciences, Inc. (CLRB)
CIK:        0001279704
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001104659-24-071822
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cellectar stockholders approve increase in share reserve by 7M shares, re-elect directors
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2021 Stock Incentive Plan, increasing shares reserved by 7,000,000 (14.5M for, 1.06M against).
- Class I directors Asher Chanan-Khan and John Neis re-elected with 15.4M and 14.9M votes for, respectively.
- Ratification of Baker Tilly US, LLP as independent auditor for FY2024 approved (25.8M for, 183k against).
- Non-binding advisory vote on executive compensation approved (15.1M for, 436k against).
- No departures or other material changes reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924071822/0001104659-24-071822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1279704/000110465924071822/tm2417372d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer